SFC Capital

SFC Angel Fund SEIS 2025.26 III

Portfolio Overview

February 2026

REGENO

Website: regeno.co.uk

Company Registration: Regeno Ltd (CRN: SC777353)

Founder(s): Adarsh Bhardwaj (CEO)

What they do: Modular linear-motion wind turbines offering low-cost, wildlife-safe renewable energy for farms and industrial users, designed for crane-free installation.

Why we invested: Early progress includes over 30 customer interviews, two signed LOIs, five farmers committed for trials, and validated prototype testing including wind-tunnel results. The business has secured multiple grants, completed an IP audit with a £10k patent award, and is advancing patent filings covering its unique energy-harvesting and crane-free installation methods. Strong market interest and clear differentiation support a credible commercial pathway despite being pre-revenue.

Co-investors: One Planet Capital, University of Strathclyde, Gabriel Investment, Scottish Enterprise

REGENO





NESTIMATE

Website: nestimate.ai

Company Registration: Nestimate Ltd (CRN: 16896806)

Founder(s): Armin Aghili (CEO), Daniel Szweda (CTO)

What they do: AI-driven estimation platform converting site videos, drawings and tender documents into fast, accurate, editable construction proposals.

Why we invested: Early commercial traction includes five paying customers, initial annual and monthly subscription revenue, and a pipeline of warm SME and enterprise leads. The founders bring 15 years of deep-tech collaboration experience and have developed a fully functional multimodal estimation MVP with proprietary datasets. Evidence of customer onboarding, proposal generation capability and rapid product iteration provides a strong foundation for scaling within a large construction SME market.

Nestimate

SFC



PREMAZ

Website: premaz.co.uk

Company Registration: Prema Cognition Ltd (CRN: 16587467)

Founder(s): Dr Julia Cooney (CEO), Cameron Kirkpatrick (CCO)

What they do: Digital cognitive assessment measuring memory precision to detect early cognitive decline and support clinical, research, and pharma use cases.

Why we invested: The product is fully functional, already deployed across three clinics, and supported by ten years of Cambridge University research with six peer-reviewed studies underpinning its scientific validity. Early commercial traction includes paid pilots, three active clinical sites, seven more onboarding, and strong inbound demand. The founding team combines medical, scientific and commercial expertise, with proprietary IP fully owned by the company and a pipeline including CRO negotiations and NHS letters of support.

PREMAZ
Precision Memory Assessment by Zest



PLATO

Website: plato.ac

Company Registration: Plato Academic Ltd (CRN: 15734258)

Founder(s): Dragos Popa (Head of Product), Nikita Dumitriu (Head of Operations)

What they do: AI platform enabling universities to deliver scalable, course-integrated academic support with insights into student needs and engagement.

Why we invested: Trials with the Universities of Sussex and Liverpool demonstrate real-world adoption across 4,500+ students, supported by strong early feedback. The founders built the entire platform in-house, with proprietary architecture, knowledge-representation models and academic-specific workflows forming defensible IP. Revenue validation includes two paid pilots and historical invoices, while institutional pipelines show active interest from additional universities. The business benefits from a clear market pull driven by sector financial pressures and a growing focus on retention and scalable support.

Co-investors: Baltic Ventures

Plato



COHERENCE ENGINE

Website: coherenceengine.tech

Company Registration: Coherence Engine Ltd (CRN: 16613025)

Founder(s): Dr Robin Sterling (CEO)

What they do: Software platform for designing and simulating quantum computing hardware, enabling scalable validation of control systems before physical build.

Why we invested: Strong founder expertise with 15 years in quantum computing, including leadership at Riverlane, underpins a credible technical vision. Early commercial validation includes four signed LOIs with major ecosystem players such as Atom Computing, Quantcore, VNQuantum and Lancaster University, alongside multiple additional prospects. Draft patent disclosures are ready for filing, and extensive industry discovery confirms a significant unmet need for systematic design tools as systems scale. The company benefits from strategic support by Cambridge Future Tech.

Co-investors: Cambridge Future Tech

Coherence Engine

MATRESA

Website: matresa-app.com

Company Registration: Matresa Limited (CRN: 16378985)

Founder(s): Mari-Carmen Sanchez-Morris (CEO)

What they do: Digital preventative maternal-health platform delivering personalised support for mothers while helping employers reduce attrition, absence and wellbeing-related productivity loss.

Why we invested: Founder has strong clinical, commercial and entrepreneurial credentials, backed by a growing advisory board with deep healthcare and corporate expertise. Early traction includes an EY pilot demonstrating improved wellbeing and productivity, supported by over ten LOIs and interest from major employers such as Deloitte, PwC and HSBC. A validated proof of concept, strong pipeline, and clearly differentiated preventative maternal-health technology – combined with plans for SaMD compliance and proprietary predictive models – provide a compelling foundation for scalable commercial adoption.

Co-investors: Angel Investors

Matresa

ADDPARTS

Website: addparts.co.uk

Company Registration: AddParts Ltd (CRN: 15566390)

Founder(s): Tom Fripp (CEO), Ben Smith (CCO)

What they do: Digital spare-parts platform enabling pharma manufacturers to cut downtime and inventory costs through secure storerooms and rapid on-demand production.

Why we invested: Early commercial traction includes £124k sales since July 2025 and onboarding of major pharmaceutical customers such as Seqirus Vaccines, Chester Medical and AstraZeneca. The company has secured two active storerooms with a £60k annual subscription and demonstrated demand through multiple pilots and a growing pipeline. A bespoke digital storeroom platform, ISO 9001 accreditation and ownership of the new system's code create meaningful defensibility, supported by a highly experienced founding team with deep sector credentials.





MYOMAKER BIO

Website: myomakers.com

Company Registration: Myomakers Ltd (CRN: 15149000)

Founder(s): Mark Lewis (CEO), Dr Andrew Capel (CSO)

What they do: Engineer human skeletal muscle organ models that replicate real tissue structure and function for pre-clinical drug discovery, toxicity and efficacy testing.

Why we invested: The company has generated £61k revenue to date, delivering two paid CRO contracts including repeat work from Italfarmaco and a completed project for DSTL. A robust pipeline validated through ICURe includes over 100 industry engagements and a weighted £570k opportunity set. The platform is backed by ~£10m UKRI R&D and protected by exclusive licensed IP, with one patent filed and another imminent. Founders bring 175 publications and extensive translational expertise, positioning the business strongly within a growing non-animal testing market.

MYOMAKER BIO

SFC



CHLOROGEN

Website: chlorogen.co.uk

Company Registration: Chlorogen Ltd (CRN: 15462377)

Founder(s): Conor Edwards (CEO)

What they do: Develops a biohybrid semiconductor platform using biological light-harvesting nanomachinery to create high-efficiency, flexible, low-energy solar cells.

Why we invested: The business has secured a £200k Innovate UK grant with the full match committed and has attracted £100k of angel investment. A demonstrator programme is fully planned with facilities and subcontractors in place for a nominal November 2025 start. Core IP development is underway, with patent filing planned across major jurisdictions. The founding team combines synthetic biology, semiconductor physics and prior TRL1-6 delivery experience, creating strong capability in an emerging advanced-materials market.

Co-investors: Angel Investors

ChloroGen

SFC



RIVULO

Website: rivulo.ai

Company Registration: Rivulo Ltd (CRN: 16569958)

Founder(s): Thomas Whiteley (CEO), Michael Miner (CCO)

What they do: Enabling non-technical teams to automate repetitive workflows using AI-powered training, browser actions and API integrations for end-to-end process automation.

Why we invested: Two paying customers validate early demand, supported by a growing pipeline including LOIs from Little Moons and JustPark at higher price points. The product is already live with a working hybrid automation engine combining browser and API execution. Founders bring strong SaaS, product and technical scaling experience, with prior exits and government-grade deployments. Forecasts demonstrate a credible route to £10k MRR within year one, supported by clear customer conversations and repeatable use cases.

Co-investors: Angel Investors

rivulo





MEANINGFUL PLANET

Website: meaningfulplanet.co.uk

Company Registration: Meaningful Planet Ltd (CRN: 15028121)

Founder(s): Nick Falkowski (CEO), Richard West (COO)

What they do: Intelligent software platform eliminating telecom overspend through SIM optimisation, real-time control, cost certainty and per-SIM emissions reporting across unified business mobile connectivity.

Why we invested: The company has achieved early traction with a fully developed MVP, paying B2B customers and £30k ARR, supported by signed agreements with eight customers and a wider pipeline spanning 26 organisations. Their MILO platform and SmartSpend algorithm offer defensible optimisation capability, with strong technical and commercial execution evidenced by £24k in first-year revenue and validated demand from channel partners. The founders bring deep B2B telecoms, product and sales-scaling experience, giving confidence in delivering projected growth.

Co-investors: Angel Investors

Meaningful Planet

SFC

HYDRA MANUFACTURING

Website: hydra-manufacturing.com

Company Registration: Hydra Manufacturing Limited (CRN: 15939081)

Founder(s): Louis Masters (CEO), Daniel Davie (CIO), Matthew Shuttleworth (CTO), Robert Kay (Chairman)

What they do: Hybrid ceramic additive manufacturing systems combining 3D printing, machining and intelligent defect correction to deliver production-ready advanced ceramic components.

Why we invested: The company has generated £67k revenue from an early machine sale and consultancy projects, supported by ten years of academic R&D and a TRL 8–9 core platform. Validation through Lucideon provides commercial credibility, with additional pilots and a £25.5k contract scheduled. Strong IP foundations include licensed university technology and upcoming patent filings. The founding team brings deep expertise across machine learning, hybrid manufacturing and ceramic process engineering, positioning the business well in a rapidly growing market






PONTIRO

Website: pontiro.com

Company Registration: Pontiro Ltd (CRN: 16083251)

Founder(s): Lewis Bowen (CEO), Adam Shannon (CTO), Evan Jenkins (COO)

What they do: Automated on-premise medical-imaging anonymisation platform enabling safe AI evaluation, secure data governance and scalable deployment across clinical environments.

Why we invested: The platform is fully deployed in NHS Wales and has anonymised over 1.8 million images across five Health Boards, demonstrating operational readiness and strong clinical validation. The company has secured two signed contracts, multiple agreed pilots and a pipeline of around forty engaged organisations, with first paid revenues expected from Cardiff & Vale UHB. Supported by Innovate UK funding and a venture-building partnership with Cyber Innovation Hub, the team brings complementary technical and commercial capability in a rapidly growing imaging-AI infrastructure market.

Co-investors: Plug and Play

Pontiro



CAMBRIDGE MEDIXINE

Website: cambridgemedixine.com

Company Registration: Cambridge Medixine Ltd (CRN: 14592661)

Founder(s): Dr Ahmet C. Berkyurek (CEO), Dr Andreas W. Claas (CSO)

What they do: Develop non-viral self-amplifying RNA therapeutics enabling safer, smaller and immune-silent RNA platforms for next-generation vaccines and treatments.

Why we invested: The company has filed a UK patent protecting its RNARISE platform and has generated early external validation through reviewer feedback, scientific programmes and engagement from major pharma including AstraZeneca, BioNTech, GSK and J&J. A clear technical roadmap exists with human and mouse cell-line benchmarking underway, supported by £190k of existing CLN funding. The founders bring deep RNA biology, vaccine and therapeutics experience, and the business has identified multiple early licensing discussions and LOEs with biotech partners.

Co-investors: Zinc VC

CamMed
CAMBRIDGE MEDIXINE

SFC



SONAS PHARMA

Company Registration: Sonas Pharmaceuticals (N.I.) Limited (CRN: NI714578)

Founder(s): Dr Chris Hayes (CEO), Dr Emma Cheetham (COO)

What they do: Developer of novel prescription cannabinoid-inspired medicines for treatment-resistant epilepsy and obesity using optimised, patentable chemical entities.

Why we invested: The company has synthesised novel compounds with encouraging preclinical efficacy, including animal data demonstrating superior seizure control versus CBD and favourable in-silico safety signals. Patent filings for both epilepsy and obesity programmes are already underway, with founders named as inventors. The team brings substantial senior-level experience from GW Pharma and Jazz, including involvement in major cannabinoid drug development and IP strategy. Strong indication markets and clear scientific validation provide a credible foundation for long-term value creation.

Co-investors: Clarendon

SONAS PHARMA



YOUR CUE

Website: yourcue.co.uk

Company Registration: Your Cue Ltd (CRN: 13799004)

Founder(s): Sonakshi Senthil (CEO), Dr Nikhit Anilbhai (Chief Medical Officer)

What they do: Wireless medical-grade wearable system enabling continuous multi-vital monitoring for neonatal, hospital ward and home-care patients through affordable sensor devices.

Why we invested: The company has secured nine Letters of Intent from hospitals and clinical partners, supported by successful early demonstrations and initial neonatal validation tests. Their Neo Alert MVP is complete with a functional software platform, and additional products are progressing through prototype stages. Founders bring strong medical, technical and commercial expertise, complemented by an experienced medtech chair and advisory team. Grant funding, LOIs and a clear regulatory and manufacturing pathway underpin credible early traction.

YOUR CUE

SFC



TRAKNOVA

Website: traknova.com

Company Registration: Traknova Ltd (CRN: 16667361)

Founder(s): Timi Adeyemo (CEO), Charles Alexis (CTO)

What they do: Unified fleet-management platform combining tracking, dash-camera monitoring and vehicle immobilisation to simplify operations and improve security for fleet operators.

Why we invested: The company has demonstrated strong early traction, generating recurring revenue from taxi, private-hire and rental customers and supporting more than 75 active vehicles. The platform unifies tracking, security and video monitoring in a single system, with proprietary software and integrations validated across multiple hardware providers. Early customer adoption, over 900 vehicles in pipeline opportunities, and clear product-market fit in a large and growing fleet-management market support compelling growth potential.

Co-investors: Angel Investors

TRAKNOVA





TOCU

Website: tocuhealth.com

Company Registration: Tocu Limited (CRN: 14757859)

Founder(s): Joanna Nicola (CEO)

What they do: Vitamin-infused transdermal patches paired with a modern consumer wellness brand focused on convenient, pill-free daily supplementation.

Why we invested: The business has generated early revenue through D2C sales supported by strong organic traction and influencer-driven demand. The founder brings prior experience scaling a multi-brand retail platform and has established UK-based manufacturing with medical-grade materials. Early wholesale interest, including engagement with major retailers and international distributors, strengthens commercial validation. The company has built a pipeline of retail and distributor discussions and demonstrates strong customer engagement across digital channels.

TOCU.

Thank you for investing with SFC Capital.

invest@sfccapital.com